Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ArQule, Inc.
Asia Deal Watch: Astellas Invests In Taysha, Gets Rights To Two AAV Gene Therapies
Plus deals involving Takeda/Zedira/Dr. Falk, Lupin/Sunovion, Eucure/Syncromune, Hetero/Johnson & Johnson, Nitto Denko/Omega, Harbour BioMed/CSPC and Pregene/Bone Therapeutics.
Portage Buys Tarus, Gaining Cancer Assets Targeting Immune Evasion
Acquisition valued at roughly $21m upfront for two clinical and two preclinical adenosine receptor antagonists.
Tech Transfer Roundup: Boehringer Teams Up With A*STAR On Targeted Oncology R&D
National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.
Finance Watch: Two Years Later, $212m More Cash For Omega’s New Life Science Fund
Private Company Edition: Omega Funds closed its seventh venture capital fund, far exceeding its $500m goal. Also, Anaveon raised a CHF110m ($119.8m) series B round, Ambys brought its series A total to $107m with $47m in additional investment and Mythic launched with a $103m series B round.
Drug Discovery Technologies
- Molecular Diversity
- Drug Discovery Technologies
- Other Names / Subsidiaries
- Cyclis Pharmaceuticals, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.